Umbilical Cord Blood-Derived Natural Killer Cells Combined with Bevacizumab for Colorectal Cancer Treatment

Autor: Zhixin Chen, Taiyuan Li, Chen Xu, Jiaping Hu, Huan-Kui Sun, Dongning Liu, Fan Zhuo
Rok vydání: 2018
Předmět:
Cytotoxicity
Immunologic
Chemokine
Adoptive cell transfer
Natural killer cell
Immunophenotyping
03 medical and health sciences
Mice
0302 clinical medicine
Antineoplastic Agents
Immunological
Cell Line
Tumor
Genetics
Umbilical Cord Blood-derived Natural Killer Cells
Medicine
Animals
Humans
Molecular Biology
030304 developmental biology
0303 health sciences
biology
Neovascularization
Pathologic
business.industry
Antibody-Dependent Cell Cytotoxicity
Interleukin
Colony-stimulating factor
Fetal Blood
Adoptive Transfer
Combined Modality Therapy
Xenograft Model Antitumor Assays
Extravasation
Bevacizumab
Killer Cells
Natural
Disease Models
Animal
medicine.anatomical_structure
030220 oncology & carcinogenesis
biology.protein
Cancer research
Molecular Medicine
Tumor necrosis factor alpha
business
Colorectal Neoplasms
Biomarkers
Zdroj: Human gene therapy. 30(4)
ISSN: 1557-7422
Popis: Colorectal cancer (CRC) is among the cancers with the highest incidence globally, and it currently ranks as the fourth leading cause of cancer-related deaths worldwide. Novel strategies for the treatment of advanced CRC are urgently needed, and adoptive transfer of allogeneic natural killer (NK) cells represents an attractive option. In this study, we successfully expanded NK cells from umbilical cord blood (UCB) with membrane-bound interleukin (IL)-21, termed eUCB-NK cells. eUCB-NK cells efficiently lysed CRC cell lines in vitro and secreted significantly higher levels of interferon-γ, tumor necrosis factor-α, granulocyte-macrophage colony stimulating factor, and chemokine ligand 3 compared with IL-2-stimulated NK cells. Adoptive transfer of these NK cells significantly inhibited the growth of HT29 xenografts, whereas LoVo tumors were not effectively controlled with eUCB-NK cells. Higher numbers of NK cells inside HT29 tumors, not seen in LoVo tumors, might contribute to the differences in response to eUCB-NK cells. Bevacizumab increased extravasation of adoptively transferred NK cells into LoVo tumors and improved the therapeutic activity of eUCB-NK cells. These results justify clinical translation of UCB-derived NK cell-based therapeutics, used alone or in combination with bevacizumab, as a novel treatment option for patients with CRC.
Databáze: OpenAIRE
Externí odkaz: